Could Immuron Limited – American Depositary Shares (NASDAQ:IMRN) Go Down After Its Newest Short Interest Report?

The stock of Immuron Limited – American Depositary Shares (NASDAQ:IMRN) registered a decrease of 62.41% in short interest. IMRN’s total short interest was 5,000 shares in September as published by FINRA. Its down 62.41% from 13,300 shares, reported previously. With 71,700 shares average volume, it will take short sellers 0 days to cover their IMRN’s short positions.

The stock increased 6.18% or $0.17 during the last trading session, reaching $2.92. About 1,177 shares traded. Immuron Limited (NASDAQ:IMRN) has declined 62.70% since September 13, 2018 and is downtrending. It has underperformed by 62.70% the S&P500.

Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company has market cap of $13.71 million. The firm operates through Research and Development, and HyperImmune Products divisions. It currently has negative earnings. It has a technology platform that enables a shorter development therapeutic cycle.

More notable recent Immuron Limited (NASDAQ:IMRN) news were published by: which released: “The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale – Benzinga” on June 18, 2019, also with their article: “BriaCell Appoints Richard J. Berman to Board of Directors – Nasdaq” published on August 12, 2019, published: “Immuron CEO Dr. Gary S. Jacob to Present at the ThinkEquity Conference on May 2, 2019 – GlobeNewswire” on April 30, 2019. More interesting news about Immuron Limited (NASDAQ:IMRN) were released by: and their article: “Kitov Pharma leads healthcare gainers; TRACON Pharmaceuticals and MiMedx Group among losers – Seeking Alpha” published on April 12, 2019 as well as‘s news article titled: “30 Stocks Moving In Wednesday’s Pre-Market Session – Benzinga” with publication date: July 17, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.